Skip to main content
. Author manuscript; available in PMC: 2010 Nov 12.
Published in final edited form as: Stroke. 2004 Mar 4;35(4):998–1004. doi: 10.1161/01.STR.0000119383.76447.05

Figure 1.

Figure 1

A, Gelatinolytic activities of purified uPA, plasminogen, and recombinant pro-MMP-2 and pro-MMP-9. Plasminogen and uPA converted pro-MMP-2 to active MMP-2 (b) and converted pro-MMP-9 to active MMP-9 (a). GM6001 inhibited MMP-2 activity. B, Effect of uPA, plasminogen (plgn, 5 U/mL), and pro-MMP-2 (1 µg/mL) or pro-MMP-9 (1 µg/mL) with plasminogen+uPA on microvessel matrix collagen, laminin, and perlecan. C, D, Effect of protease inhibitors APMSF (100 µmol/L) and GM6001 (100 µmol/L) on perlecan. n=4 (B) or n=3 (C, D) animals each. *2P<0.05 (C, D).

HHS Vulnerability Disclosure